ArticleCancer discovery2021

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

Prasad S Adusumilli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.